December 8, 2021 -- Metis Therapeutics has launched with $86 million in series A financing to harness artificial intelligence (AI) and machine learning to redefine drug discovery and delivery and develop optimal therapies for patients with serious diseases.
The Metis platform combines AI data-driven algorithms, mechanism-driven quantum mechanics, and molecular dynamic simulations to calculate active pharmaceutical ingredient (API) properties and elucidate API target and API excipient interactions. In addition, the platform can predict chemical, physical, and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments, which can enable efficient lead optimization, candidate selection, and formulation design, Metis said.
PICC PE and China Life led the financing; they were joined by Sequoia Capital China, Lightspeed, 5Y Capital, Frees Fund, and CMBI Zhaoxin Wuji Fund.
Copyright © 2021 scienceboard.net